What’s the Latest on COVID-19?
Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.
Arbel R, Wolff Sagy Y, Hoshen M, et al. N Engl J Med. 2022;387(9):790-798.
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
End of the National Public Health Emergency for COVID-19: What Does It Mean for the Public?
Bonavitacola, J. Am J Manag Care. March 2, 2023.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): Preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial
Butler C, Hobbs R, Gbinigie O, et al. SSRN. 2022. [Epub ahead of print].
Early remdesivir to prevent progression to severe Covid-19 in outpatients.
Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB.
Imai M, Ito M, Kiso M, et al. N Engl J Med. 2022. [Epub ahead of print]
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.
Data and clinical considerations for additional doses in immunocompromised people.
Oliver S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; July 22, 2021.
Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
Qu P, Evans JP, Faraone J, et al. bioRxiv. 2022:2022.2010.2019.512891.
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q, Iketani S, Li Z, et al. bioRxiv. 2022:2022.2011.2023.517532.
Improved neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine.
Zou J, Kurhade C, Patel S, et al. bioRxiv. 2022:2022.2011.2017.516898.
Clinical Trials for investigational monoclonal antibodies
SUPERNOVA: AZD5156/AZD3152
ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05648110
VYD222
ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05791318
ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06039449
Clinical Practice Guidelines
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States.
Centers for Disease Control and Prevention (CDC).
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Clinician Resources
COVID data tracker.
CDC.
Federal response to COVID-19: therapeutics clinical implementation guide.
Department of Health and Human Services (DHHS).
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
US Food and Drug Administration (FDA).
Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM.
FDA.
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
OpenData Portal
NIH.
What’s the Latest on COVID-19? - West Region
Current Prevention and Treatment Strategies
| Faculty: | Eric S. Daar, MD; Monica Gandhi, MD. MPH |
| Release: | 11/28/2022 |
| Expiration: | 02/28/2023 |
What’s the Latest on COVID-19? - Midwest Region
Current Prevention and Treatment Strategies
| Faculty: | Daniel Kaul, MD; Raymund R. Razonable, MD, FIDSA, FAST |
| Release: | 11/28/2022 |
| Expiration: | 02/28/2023 |
What’s the Latest on COVID-19? - South Region
Current Prevention and Treatment Strategies
| Faculty: | Roger J. Bedimo, MD; Leigh Lewis Speicher, MD, MPH |
| Release: | 11/29/2022 |
| Expiration: | 03/01/2023 |
What’s the Latest on COVID-19? - Northeast Region
Current Prevention and Treatment Strategies
| Faculty: | Elizabeth P. Clayborne, MD, MA; Lewis W. Teperman, MD |
| Release: | 12/08/2022 |
| Expiration: | 03/08/2023 |
Novel COVID-19 Subvariants and the Changing Treatment Landscape
A COVID-19 "Breaking News" Update
| Faculty: | Eric S. Daar, MD |
| Release: | 12/23/2022 |
| Expiration: | 12/23/2023 |
Updates to Preventing and Treating COVID-19 in Immunocompromised Patients
Effect of XBB.1.5, BQ.1, and BQ.1.1 Subvariants
| Faculty: | Lewis W. Teperman, MD, FACS |
| Release: | 01/27/2023 |
| Expiration: | 01/27/2024 |
Answers to Common Clinical Challenges in COVID-19
A COVID-19 "Breaking News" Update
| Faculty: | Elizabeth P. Clayborne, MD, MA |
| Release: | 02/28/2023 |
| Expiration: | 02/28/2024 |
Anti-SARS-CoV-2 mAbs as Preexposure Prophylaxis
Proof of Concept and Future Directions
| Faculty: | Raymund R. Razonable, MD, FIDSA, FAST |
| Release: | 03/10/2023 |
| Expiration: | 03/10/2024 |
The End of the COVID-19 Public Health Emergency
What Does This Mean for Your Practice?
| Faculty: | Leigh Lewis Speicher, MD, MPH |
| Release: | 05/11/2023 |
| Expiration: | 05/11/2024 |
The Latest Data in Anti-SARS-COV-2 Monoclonal Antibodies
A COVID-19 "Breaking News" Update
| Faculty: | Roger J. Bedimo, MD |
| Release: | 02/15/2024 |
| Expiration: | 02/15/2025 |
